John Snisarenko Insider Profile
4 Followers
John Snisarenko, Director at Alimera, holds 30.32K shares in Oyster Point Pharma (Ticker: OYST), holds 10.00K shares in Alimera (Ticker: ALIM).
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-3.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
John Snisarenko does not currently own shares as a corporate insider.
A breakdown of John Snisarenko's holdings
Insider Roles
John Snisarenko does not currently hold a role as a corporate insider.
Roles that John Snisarenko holds in companies
Most Profitable Insider Trade
Stock:
Oyster Point Pharma
(OYST)
(OYST)
Rating:Informative Buy
Date:Nov 05, 2019 - Nov 05, 2020
Return:+34.90%
The most profitable trade made by John Snisarenko
John Snisarenko's Trading History
Alimera
Nov 25, 2019
―
Informative Buy
49.50K
$55.40K
Oyster Point Pharma
Jan 11, 2022
―
Uninformative Buy
―
$338.70K
List of latest transactions for each holding click on a transaction to see John Snisarenko's performance on stock
You May Also Like
John Snisarenko insider profile FAQ
What is the percentage of profitable transactions made by John Snisarenko?
The percentage of profitable transactions made by John Snisarenko is 33%.
What is the average return per transaction made by John Snisarenko?
The average return per transaction made by John Snisarenko is -3.80%.
What stocks does John Snisarenko hold?
John Snisarenko holds: ALIM, OYST stocks.
What was John Snisarenko’s latest transaction?
John Snisarenko latest transaction was an Uninformative Buy of ―.
What was John Snisarenko's most profitable transaction?
John Snisarenko’s most profitable transaction was an Informative Buy of OYST stock on November 5, 2019. The return on the trade was 34.90%.
What is John Snisarenko's role in Alimera?
John Snisarenko's role in Alimera is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.